PSMA expression on neovasculature of solid tumors

• Christophe Van de Wiele ^[1] ; Mike Sathekge ^[1] ; Bart de Spiegeleer ^[2] ; Pieter Jan De Jonghe ^[1] ; Philip R. Debruyne ^[4] ; Marleen Borms ^[3] ; Laurence Beels ^[1] ; Alex Maes ^[1]
  1. [1] University of Pretoria

     University of Pretoria

     City of Tshwane, Sudáfrica

     
  2. [2] Ghent University

     Ghent University

     Arrondissement Gent, Bélgica

     
  3. [3] KU Leuven

     KU Leuven

     Arrondissement Leuven, Bélgica

     
  4. [4] Medical Oncology, AZ Groeninge, Kortrijk

  Mostrar afiliaciones +
• Localización: Histology and histopathology: cellular and molecular biology, ISSN-e 1699-5848, ISSN 0213-3911, Vol. 35, Nº. 9, 2020, págs. 919-927
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • . The use of prostate specific membrane antigen (PSMA) binding agents, labelled with diagnostic and therapeutic radio-isotopes is opening the potential for a new era of personalized management of prostate carcinoma. A wide variety of immunohistochemistry studies have shown PSMA also to be upregulated on the endothelial cells of the neovasculature of a wide variety of other solid tumors where it may facilitate endothelial cell sprouting and invasion through its regulation of lytic proteases that have the ability to cleave the extracellular matrix.

    Similar to the introduction of PSMA-targeting theranostics in prostate carcinoma, overexpression of PSMA on newly formed tumor vessels may serve as a target for imaging and subsequent treatment of cancer through the use of agents that are capable of blocking PSMA in its function or through PSMA-mediated delivery of chemotherapeutics or radiation agents. In this review, the available data on PSMA expression on tumor neovasculature in human solid tumors assessed by using immunohistochemistry are discussed.